$Outcomes of Refractory and Relapsed Hodgkin Lymphoma With Autologous Stem-Cell Transplantation: A Single Institution Experience$

Outcomes of Refractory and Relapsed Hodgkin Lymphoma With Autologous Stem-Cell Transplantation: A Single Institution Experience

PURPOSE: Hodgkin lymphoma is the most common cancer in children, adolescents, and young adults. Overall survival is approximately 80% to 90%. A subset of these patients has refractory disease or experience disease relapse. Conventional salvage therapies and autologous stem-cell transplantation is us...

Full description

Bibliographic Details
Main Authors:	Rabia Wali, Haleema Saeed, Naveed Patrus, Shehla Javed, Saadiya Javed Khan
Format:	Article
Language:	English
Published:	American Society of Clinical Oncology 2019-11-01
Series:	Journal of Global Oncology
Online Access:	http://ascopubs.org/doi/10.1200/JGO.19.00051

Similar Items

CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
by: Luca Castagna, et al.
Published: (2015-02-01)

Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation
by: Eva Domingo-Domènech, et al.
Published: (2020-05-01)

Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
by: Anna Sureda, et al.
Published: (2020-11-01)

Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?
by: Yogesh Jethava, et al.
Published: (2017-06-01)

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
by: Evgeny Klyuchnikov, et al.
Published: (2011-01-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

High dose chemotherapy and autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: Emerging questions, newer agents, and changing paradigm
by: Saad Akhtar
Published: (2017-12-01)

Relapsed and refractory classical Hodgkin lymphoma immunotherapy
by: Kirill Lepik
Published: (2020-10-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

New agents in relapsed/refractory Hodgkin's lymphoma
by: Irene Biasoli, et al.

The Efficacy and Safety of Busulfan-Etoposide-Melphalan Regimen in Autologous Stem Cell Transplantation in Relapsed/ Refractory Hodgkin and Non-Hodgkin Lymphoma Patients: “A Single-Center Experience”
by: Ali Eser, et al.
Published: (2021-05-01)

The outcome of relapsed/refractory hodgkin's lymphoma patients post autologous bone marrow transplantation in a Baghdad Medical City Complex Center
by: Maryam Abdhlkadhum, et al.
Published: (2021-01-01)

Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis
by: Jianhong Wang MD, et al.
Published: (2020-11-01)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01)

Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation: A current management perspective
by: Madiha Iqbal, et al.
Published: (2021-06-01)

Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma
by: Afonso José Pereira Cortez, et al.
Published: (2011-02-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
by: Simon Hallam
Published: (2018-08-01)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
by: Roberta Fedele, et al.
Published: (2015-01-01)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
by: Siddiqi T, et al.
Published: (2014-02-01)

Linfoma de Hodgkin recidivado após transplante autólogo de medula óssea Relapsed Hodgkin's lymphoma after autologous bone marrow transplantation
by: Abrahão E. Hallack Neto, et al.
Published: (2008-08-01)

EAM conditioning regimen followed by autologous hematopoietic Stem Cell Transplantation for relapsed, refractory and high risk lymphomas
by: Mohamed BEKADJA, et al.
Published: (2014-08-01)

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
by: Karantanos T, et al.
Published: (2017-05-01)

rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma
by: Zhu J, et al.
Published: (2019-09-01)

The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin
by: Michelle Furtado, et al.
Published: (2012-01-01)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin
by: Michelle Furtado, et al.
Published: (2012-01-01)

Genomic Instability: The Driving Force behind Refractory/Relapsing Hodgkin’s Lymphoma
by: Sabine Mai, et al.
Published: (2013-06-01)

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01)

Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma
by: Gutierrez A, et al.
Published: (2014-11-01)

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
by: Patrick B. Johnston, et al.
Published: (2018-05-01)

Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
by: Ramazan Acar, et al.
Published: (2020-12-01)

Autologous stem-cell transplantation in Hodgkin’s lymphoma: analysis of a therapeutic option
by: Adriano de Moraes Arantes, et al.
Published: (2011-06-01)

Autologous stem-cell transplantation in Hodgkin's lymphoma: analysis of a therapeutic option
by: Adriano de Moraes Arantes, et al.

Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontiﬁcia Universidad Católica de Chile
by: Pablo Ramirez, et al.
Published: (2015-06-01)

Safety and Efficacy of BeEAC as a Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Lymphomas
by: VO Sarzhevskii, et al.
Published: (2019-03-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)